How to Find the Best Small-Cap Stocks to Buy

Wall Street's best small-cap stocks to buy include biotech, real estate and software names.

best small cap stocks
(Image credit: Getty Images)

The second half of 2025 could be much more favorable for stockpickers looking for the best small-cap stocks to buy.

That might sound counterintuitive after the way small caps performed through the first half of the year. After all, small caps as an asset class have been a dud. They went nowhere as mega-cap stocks pushed the broader market to record highs.

To recap: the S&P 500 gained almost 8.6% on a price basis through early August, while the tech-heavy Nasdaq Composite rose more than 11%. The Dow Jones Industrial Average rose just 3.4%, hurt partly by its price-weighted construction.

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%
https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of expert advice - straight to your e-mail.

Sign up

But while select Magnificent 7 stocks such as Nvidia (NVDA) and Microsoft (MSFT) helped drive the market's gains, small caps – which tend to be more sensitive to the economic cycle and interest rates – traded sideways. Indeed, the small-cap benchmark Russell 2000 Index – struggling to stay positive for months – was slightly negative through the first eight months of the year.

If there is a sliver of a silver lining to the Russell 2000's underperformance, it's that small caps are now trading at bargain basement prices.

"As the premium on large caps continues to expand, small cap equities become increasingly attractive on a relative basis," writes Jeff Buchbinder, chief equity strategist for LPL Financial. "Their lower valuations may signal undiscovered value or underappreciated growth potential, particularly in sectors poised to benefit from domestic policy tailwinds."

And with the Federal Reserve expected to enact several incremental cuts to the federal funds rate before year-end, small caps should have at least one catalyst on the horizon.

Best small-caps stocks to buy

In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.

Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell. Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.

In other words, lower scores are better than higher scores.

We further limited ourselves to stocks with at least 12 Strong Buy recommendations (in order to ensure adequate analyst coverage and sample size). Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data on the top names.

Our screen of the Street's best small-cap stocks served up a list dominated by the healthcare sector, mostly pharmaceutical and biotechnology companies. That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.

In other cases, some of these names – a gaming stock, real estate – might just surprise you.

And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.

Swipe to scroll horizontally
Wall Street's top-rated small-cap stocks

Company (Ticker)

Analysts' Consensus Recommendation Score

Subsector

Analysts' Consensus Recommendation

Waystar Holding (WAY)

1.14

Healthcare software

Strong Buy

Kymera Therapeutics (KYMR)

1.20

Biotechnology

Strong Buy

Denali Therapeutics (DNLI)

1.21

Biotechnology

Strong Buy

Genius Sports (GENI)

1.24

Casinos and gaming

Strong Buy

Axsome Therapeutics (AXSM)

1.26

Pharmaceuticals

Strong Buy

Xenon Pharmaceuticals (XENE)

1.26

Biotechnology

Strong Buy

Avidity Biosciences (RNA)

1.28

Biotechnology

Strong Buy

Wave Life Sciences (WVE).

1.31

Pharmaceuticals

Strong Buy

Arcellx (ACLX)

1.32

Biotechnology

Strong Buy

Privia Health Group (PRVA)

1.38

Healthcare services

Strong Buy

BridgeBio Pharma (BBIO)

1.41

Biotechnology

Strong Buy

Guardant Health (GH)

1.42

Healthcare services

Strong Buy

Essential Properties Realty Trust (EPRT)

1.50

Diversified RIET

Strong Buy

Dan Burrows
Senior Investing Writer, Kiplinger.com

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.

A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.

Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.

In his current role at Kiplinger, Dan writes about markets and macroeconomics.

Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.

Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.